Literature DB >> 2233472

Cost comparison of intravenous antibiotic administration.

R J Plumridge1.   

Abstract

The cost of preparing and administering intravenous antibiotics in an Australian teaching hospital was determined. The costs associated with acquisition, delivery (administration system, ancillary equipment, labour), and laboratory monitoring for potential toxicity were calculated. Standard regimens based on antibiotic guidelines were used to compile the daily total cost. The results indicate that these components affect the daily total cost of individual antibiotics in different ways. Acquisition cost is often a poor predictor of total cost, which ranges from 1.2 times to almost eight times the acquisition cost. Less frequent administration reduces total costs substantially, as does slow injection compared with infusion. Laboratory costs constitute between 3.6% and 23% of the daily total cost and are most pronounced with antibiotics that have low acquisition costs. Antibiotic cost containment should not focus on acquisition cost alone. Daily total cost to administer antibiotics is a more appropriate and accurate costing method. Hospitals must acknowledge the need for innovative resource allocation methods which recognise this fact.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233472

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  21 in total

1.  A multidisciplinary hospital-based antimicrobial use program: Impact on hospital pharmacy expenditures and drug use.

Authors:  S Salama; C Rotstein; L Mandell
Journal:  Can J Infect Dis       Date:  1996-03

Review 2.  Pharmacoeconomics of intravenous drug administration.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 3.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 4.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 5.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

6.  Using pharmacoeconomics to assess the comparative value of antibacterials. A UK perspective.

Authors:  P Davey
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 7.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

8.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 9.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

10.  Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones.

Authors:  K M Jensen; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.